Ftse Mib
33.812,44
0,12%
DAX
18.417,55
0,62%
S&P 500
5.459,10
1,11%
NASDAQ
17.357,88
1,03%
Bitcoin
68.451,86
0,79%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pharvaris NV (PHVS) Pharvaris NV (PHVS) Notizie

PHVS

Pharvaris NV (PHVS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PHVS
DataOraFonteTitoloSimboloCompagnia
11/06/202412:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
11/06/202412:50GlobeNewswire Inc.Pharvaris Announces Annual Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
04/06/202412:50GlobeNewswire Inc.Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent CongressesNASDAQ:PHVSPharvaris NV
24/05/202423:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
13/05/202412:50GlobeNewswire Inc.Pharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
08/05/202422:10GlobeNewswire Inc.Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202422:10GlobeNewswire Inc.Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202422:08GlobeNewswire Inc.Pharvaris Appoints David Nassif, J.D., as Chief Financial OfficerNASDAQ:PHVSPharvaris NV
04/04/202412:50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceNASDAQ:PHVSPharvaris NV
18/03/202411:50GlobeNewswire Inc.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesNASDAQ:PHVSPharvaris NV
06/03/202422:40Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PHVSPharvaris NV
06/03/202412:50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
05/03/202412:50GlobeNewswire Inc.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024NASDAQ:PHVSPharvaris NV
22/02/202412:50GlobeNewswire Inc.Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingNASDAQ:PHVSPharvaris NV
16/02/202412:50GlobeNewswire Inc.Pharvaris Announces Extraordinary Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
26/01/202412:50GlobeNewswire Inc.Pharvaris to Present at the WSAAI Annual Meeting 2024NASDAQ:PHVSPharvaris NV
22/01/202413:35Dow Jones NewsPharvaris Says FDA Lifted Clinical Hold on Application for DeucrictibantNASDAQ:PHVSPharvaris NV
22/01/202412:50GlobeNewswire Inc.Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
05/01/202412:50GlobeNewswire Inc.Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesNASDAQ:PHVSPharvaris NV
09/12/202300:00GlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
07/12/202322:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHVSPharvaris NV
06/12/202313:08Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PHVSPharvaris NV
06/12/202313:02GlobeNewswire Inc.Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded WarrantsNASDAQ:PHVSPharvaris NV
06/12/202312:50GlobeNewswire Inc.Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
30/11/202312:50GlobeNewswire Inc.Pharvaris to Present at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
15/11/202312:50GlobeNewswire Inc.Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations OfficerNASDAQ:PHVSPharvaris NV
09/11/202317:00GlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific MeetingNASDAQ:PHVSPharvaris NV
02/11/202311:50GlobeNewswire Inc.Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
30/10/202311:50GlobeNewswire Inc.Pharvaris To Present at the ACAAI 2023 Annual Scientific MeetingNASDAQ:PHVSPharvaris NV
13/10/202312:50GlobeNewswire Inc.Pharvaris To Present at the APAAACI 2023 International ConferenceNASDAQ:PHVSPharvaris NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PHVS

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
SPM
Saipem
BIT
ISP
Intesa Sanpaolo
BIT
IVG
Iveco Group NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
RACE
Ferrari NV
BIT
TEN
Tenaris
BIT
ARIS
Ariston Holding NV
BIT
PRY
Prysmian
BIT
MONC
Moncler
BIT
LDO
Leonardo
BIT
TRN
Terna Trasmissione Elett...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network